A new platform for medical technology.
Caldera is a platform that helps medtech investors understand opportunities, grow companies, and build the capabilities to sustain them.
Explore the platform ↗The Network
Our network is built with our clinical advisory board and reaches into nearly every therapeutic area and specialty in healthcare. It is Caldera's most valuable asset, and the rest of our work depends on it.
Our intelligence, growth, and training work all starts with what clinicians and hospital buyers tell us.
What we learn from clinicians shapes how we help companies grow and what we teach their commercial teams about how hospitals buy.
The clinical advisory board
Growth
Senior sales reps from the network who take new products into health systems.
The Academy 2027
Training
Sales and marketing training built around how hospitals decide what to buy.
The Platform
i.
Intelligence
Usability House
Diligence on a medtech deal means knowing whether the category is worth entering, which company to own, and whether clinicians will adopt. We hold standing relationships with hundreds of clinicians, hospital buyers, and health system leaders across specialties, people who evaluate new technology and tell us what they see. We also run human factors studies in our own labs and ethnographic research in the hospitals and clinics where devices are used. That research shows whether clinicians can use a product well and what would improve it, which matters during diligence and again after the deal closes.
ii.
Growth
Lumen Health Group
Growing a portfolio company during the hold means opening new accounts, health systems, and markets, and a sales force that can do that takes years to build. Lumen Health Group has one in place. Its senior reps work across therapeutic areas, and each has sold into hospitals for a decade or more and has the relationships that come with that. They open the next market while the company hires its own team. The cost is variable and there is no ramp-up period, so the results can be measured against the investment thesis.
iii.
Training
The Academy
Most portfolio companies' sales teams were built to sell to surgeons. Today the purchase is usually decided by a value analysis committee, based on a packet that marketing wrote and a rep has to defend. The Academy brings a company's marketing and sales people together with the chief medical officers, nursing executives, and supply chain leaders who approve these purchases, and those leaders explain what they need to see before they approve one. Marketing learns what the packet has to include, and sales learns how to use it. The Academy adds to a company's own training and covers what that training usually leaves out.
The Partnership
Select a partner to read more.
Talk to us
If you own a medtech company or are considering one, tell us about it here. A partner reads every message.